Karo Pharma’s rights issue, for which the subscription period ended 29 May 2018, was fully subscribed. 53,589,146 shares, corresponding to approximately 97.8 percent of the shares issued, were subscribed for with subscription rights. The remaining 1,188,448 shares, corresponding to approximately 2.2 percent of the shares issued in the rights issue, have been alloted to subscribers who have subscribed for shares without subscription rights. In total, the rights issue have been subscribed to approximately 121.8 percent. Karo Pharma will through the rights issue raise approximately SEK 1,315m before deduction of issue costs.
Allotment of shares subscribed for without subscription rights has been made in accordance with the principles determined by the board of directors on 4 April 2018 and approved by the AGM on 3 May 2018 and as outlined in the prospectus which was published on 11 May 2018. Notification regarding allocation of shares to the subscribers who have subscribed for shares without subscription rights will only be sent to the subscribers who have been allotted shares. Through the rights issue, Karo Pharma’s share capital increases with SEK 21,910,796.356623, from SEK 43,821,592.713245 to a total of SEK 65,732,389.069868, and the number of shares will increase with 54,777,594 shares, from 109,555,188 shares to a total of 164,332,782 shares.
The new shares subscribed for with subscription rights are expected to be registered with the Swedish Companies Registration Office (Sw. Bolagsverket) around 5 June 2018. The last day of trading in paid subscribed shares (BTAs) is expected to be 8 June 2018. The new shares subscribed for with subscription rights are expected to start trading on Nasdaq Stockholm on 14 June 2018.
The new shares subscribed for without subscription rights are expected to be registered with the Swedish Companies Registration Office around 12 June 2018 and are expected to start trading on Nasdaq Stockholm on 14 June 2018
Financial and legal advisors
SEB Corporate Finance and Swedbank Corporate Finance are Joint Global Coordinators and Hamilton Advokatbyrå is legal advisor to Karo Pharma in relation to the rights issue.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Peter Blom, CEO, +46 (0) 70-655 56 98 or email@example.com
ABOUT KARO PHARMA
Karo Pharma is a Specialty Pharmaceutical company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.
This information is information that Karo Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the above contact person´s agency, at 08:00 CEST on 1 June 2018. This press release is also available at www.karopharma.se and www.newsroom.cision.com.
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Karo Pharma AB. Any invitation to the persons entitled to subscribe for shares in Karo Pharma AB is made solely through the prospectus which Karo Pharma AB published on 11 May 2018.
This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.
No subscription rights, BTAs (interim shares) or new shares have or will be registered under the United States Securities Act of 1933 (“Securities Act”) or securities legislation in any state or other jurisdiction in the United States and may not be offered, subscribed, used, pledged, sold, resold, allotted, delivered or transferred, directly or indirectly, into or within the United States, other than pursuant to an exemption from, or in a transaction that is subject to, the registration requirements of the Securities Act. The offering is not aimed for individuals with residence in Australia, Hong Kong, Switzerland, and Singapore nor in any other jurisdiction where participation would require additional prospectus, registration or other arrangements aside of the Swedish law system.